Sugi Predict

Sugi Predict / Compounds / SCHEMBL1098144

SCHEMBL1098144

SCHEMBL1098144

OCc1ccc(-c2ccnc(Cl)n2)s1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ CYP2A6 P11509 1/20 0.49
▸ MEN1 O00255 2/20 0.44
▸ ALDH1A1 P00352 2/20 0.44
▸ MAPT P10636 2/20 0.44
▸ KMT2A Q03164 2/20 0.44
▸ GLA P06280 1/20 0.44
▸ HPGD P15428 1/20 0.44
▸ HDAC6 Q9UBN7 1/20 0.44
▸ DPP4 P27487 2/20 0.40
▸ L3MBTL1 Q9Y468 1/20 0.38
▸ AKT3 Q9Y243 2/20 0.36
▸ HIF1A Q16665 3/20 0.36
▸ EPAS1 Q99814 3/20 0.36
▸ RECQL P46063 1/20 0.33
▸ SRC P12931 1/20 0.33
▸ ZAP70 P43403 1/20 0.33
▸ SYK P43405 1/20 0.33
▸ MAPK9 P45984 1/20 0.33
▸ MAPK10 P53779 1/20 0.33
▸ SORD Q00796 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1108274 0.83 MEN1 (0.39) CYP2A6MEN1ALDH1A1MAPTKMT2A
SCHEMBL15087871 0.80 DPP4 (0.44) CYP2A6MEN1ALDH1A1MAPTKMT2A
SCHEMBL2977591 0.78 SMN1; SMN2 (0.39) CYP2A6MEN1ALDH1A1MAPTKMT2A
SCHEMBL4482126 0.78 IKBKB (0.45) CYP2A6MEN1ALDH1A1MAPTKMT2A
SCHEMBL2984634 0.77 AKT3 (0.40) CYP2A6MEN1ALDH1A1MAPTKMT2A
SCHEMBL2984079 0.77 ALDH1A1 (0.58) CYP2A6MEN1ALDH1A1MAPTKMT2A
SCHEMBL2202715 0.76 MAOA (0.40) CYP2A6MEN1ALDH1A1MAPTKMT2A
SCHEMBL2975938 0.76 MEN1 (0.40) MEN1ALDH1A1MAPTKMT2AL3MBTL1
SCHEMBL2980443 0.75 DKK1 (0.43) MEN1ALDH1A1MAPTKMT2AGLA
SCHEMBL1099147 0.74 GAA (0.33) MEN1ALDH1A1MAPTKMT2ADPP4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2022231242-A1 INDAZOLE COMPOUND HAVING LRRK2 INHIBITORY ACTIVITY 주식회사 스탠다임 2022-11-03 — — WO disclosed
WO-2022231242-A1 INDAZOLE COMPOUND HAVING LRRK2 INHIBITORY ACTIVITY 주식회사 스탠다임 2022-11-03 — — WO disclosed
US-20220241291-A1 OXYGEN LINKED PYRIMIDINE DERIVATIVES SOBI, INC. 2022-08-04 — — US disclosed
US-11135227-B2 Oxygen linked pyrimidine derivatives CTI BIOPHARMA CORP. (US) 2021-10-05 — — US disclosed
US-20200071339-A1 OXYGEN LINKED PYRIMIDINE DERIVATIVES CTI BIOPHARMA CORP. (US) 2020-03-05 — — US disclosed
US-20170112846-A1 OXYGEN LINKED PYRIMIDINE DERIVATIVES CTI BIOPHARMA CORP. (US) 2017-04-27 — — US disclosed
US-20170112846-A1 OXYGEN LINKED PYRIMIDINE DERIVATIVES CTI BIOPHARMA CORP. (US) 2017-04-27 — — US disclosed
US-9573964-B2 Oxygen linked pyrimidine derivatives CTI BIOPHARMA CORP. (US) 2017-02-21 — — US disclosed
US-9573964-B2 Oxygen linked pyrimidine derivatives CTI BIOPHARMA CORP. (US) 2017-02-21 — — US disclosed
EP-1951729-B1 OXYGEN LINKED PYRIMIDINE DERIVATIVES CELL THERAPEUTICS INC (US) 2014-06-25 — — EP disclosed
US-8415338-B2 Oxygen linked pyrimidine derivatives CELL THERAPEUTICS, INC. (US) 2013-04-09 — — US disclosed
US-8415338-B2 Oxygen linked pyrimidine derivatives CELL THERAPEUTICS, INC. (US) 2013-04-09 — — US disclosed
US-20120196855-A1 OXYGEN LINKED PYRIMIDINE DERIVATIVES S*BIO PTE LTD. (SG) 2012-08-02 — — US disclosed
US-20120196855-A1 OXYGEN LINKED PYRIMIDINE DERIVATIVES S*BIO PTE LTD. (SG) 2012-08-02 — — US disclosed
US-8153632-B2 Oxygen linked pyrimidine derivatives S*BIO PTE LTD. (SG) 2012-04-10 — — US disclosed
US-8153632-B2 Oxygen linked pyrimidine derivatives S*BIO PTE LTD. (SG) 2012-04-10 — — US disclosed
US-8153632-B2 Oxygen linked pyrimidine derivatives S*BIO PTE LTD. (SG) 2012-04-10 — — US disclosed
US-20090075999-A1 OXYGEN LINKED PYRIMIDINE DERIVATIVES S*BIO PTE LTD. (SG) 2009-03-19 — — US disclosed
US-20090075999-A1 OXYGEN LINKED PYRIMIDINE DERIVATIVES S*BIO PTE LTD. (SG) 2009-03-19 — — US disclosed
WO-2007058627-A1 OXYGEN LINKED PYRIMIDINE DERIVATIVES S*BIO PTE LTD (SG) 2007-05-24 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220241291-A1 OXYGEN LINKED PYRIMIDINE DERIVATIVES DPYD, TK2, TK1 CYP2A6 2330/4885MEN1 4071/4885ALDH1A1 1035/4885
US-20090075999-A1 OXYGEN LINKED PYRIMIDINE DERIVATIVES DPYD, TK2, TK1 CYP2A6 2330/4885MEN1 4071/4885ALDH1A1 1035/4885
US-20170112846-A1 OXYGEN LINKED PYRIMIDINE DERIVATIVES DPYD, TK2, TK1 CYP2A6 2330/4885MEN1 4071/4885ALDH1A1 1035/4885
US-20120196855-A1 OXYGEN LINKED PYRIMIDINE DERIVATIVES DPYD, TK2, TK1 CYP2A6 2330/4885MEN1 4071/4885ALDH1A1 1035/4885
US-11135227-B2 Oxygen linked pyrimidine derivatives DPYD, TK2, TK1 CYP2A6 2330/4885MEN1 4071/4885ALDH1A1 1035/4885
US-20200071339-A1 OXYGEN LINKED PYRIMIDINE DERIVATIVES DPYD, TK2, TK1 CYP2A6 2330/4885MEN1 4071/4885ALDH1A1 1035/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.